Dr. Lyudmila Bazhenova, professor of Medicine and thoracic oncologist with the University of California San Diego, and active principal investigator in advanced immunotherapy-based clinical trials, highlights immunotherapy-related adverse events (AEs) for the Oncology Learning Network.
Dr. Bazhenova reports that immunotherapy is here to stay—that the breakthroughs with this class of therapy has been profound for cancer patients and specifically for this talk—non-small-cell lung cancer. She notes that immunotherapy now moves from second-line setting to first-line setting (e.g. the first treatment).
AEs & Immunotherapy
Of course, there can be any number of AEs, and Dr. Bazhenova reports that physicians should refer to resources such as the NCCN Guidelines, asthma guidelines, etc. that help explain to clinicians how to correctly manage immune-related adverse events.
What is Lacking?
According to Dr. Bazhenova, there is still a lack of knowledge—and hence uncertainty—when it comes to the use of and safety associated with use of immunotherapies on cancer patients with pre-existing autoimmune conditions, patients with HIV and hepatitis B and hepatitis C. She declares ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).